Get the Stockscreener App
1.15
13.53%
-0.18
Pre-market:
1.12
-0.03
-2.61%
Trinity Biotech Plc Adr stock is traded at $1.15, with a volume of 531.19K.
It is down -13.53% in the last 24 hours and up +40.60% over the past month.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
See More
Previous Close:
$1.33
Open:
$1.28
24h Volume:
531.19K
Relative Volume:
0.11
Market Cap:
$2.60M
Revenue:
$54.43M
Net Income/Loss:
$-36.70M
P/E Ratio:
-0.392
EPS:
-2.9334
Net Cash Flow:
$-19.17M
1W Performance:
-25.32%
1M Performance:
+40.60%
6M Performance:
+74.24%
1Y Performance:
-33.91%
1-Day Range:
$1.1151
$1.309
1-Week Range:
$1.1151
$1.53
52-Week Range:
$0.48
$3.44
Trinity Biotech Plc Adr Stock (TRIB) Company Profile
Name
Trinity Biotech Plc Adr
Sector
Industry
Phone
-
Address
-
Compare TRIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRIB
Trinity Biotech Plc Adr
|
1.15 | 5.22M | 54.43M | -36.70M | -19.17M | -2.9334 |
|
ABT
Abbott Laboratories
|
132.81 | 228.80B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.29 | 158.04B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.34 | 149.08B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.85 | 119.71B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
80.96 | 48.01B | 5.69B | 1.41B | 577.90M | 6.95 |
Trinity Biotech Plc Adr Stock (TRIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-15 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-03-15 | Initiated | Raymond James | Outperform |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jul-22-08 | Reiterated | Roth Capital | Buy |
| Mar-17-08 | Reiterated | Roth Capital | Buy |
| Dec-10-07 | Reiterated | Roth Capital | Buy |
| Oct-26-07 | Reiterated | Roth Capital | Buy |
View All
Trinity Biotech Plc Adr Stock (TRIB) Latest News
TRINITY B ADR : Trinity Biotech plc to Present at Sidoti & Company's Micro-Cap Conference on January 10, 2011 - MarketScreener
Trinity Biotech plc Appoints Paul Tivnan as Non-Executive Director - MarketScreener
Trinity Biotech appoints Paul Tivnan to board of directors - Investing.com
Trinity Biotech Appoints Paul Tivnan as Non-Executive Director - MarketScreener
Trinity Biotech receives approval for offshore manufacturing of HIV test - Investing.com
Regulatory Approval Granted for Commencement of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation - MarketScreener
TRIB’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Trinity Biotech stock soars after NY regulatory approval for preeclampsia test By Investing.com - Investing.com South Africa
Trinity Biotech stock soars after NY regulatory approval for preeclampsia test - Investing.com India
Trinity Biotech receives NY approval for preeclampsia test - Investing.com
Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service - GlobeNewswire Inc.
Trinity Biotech stock rises on successful CGM calibration-free trial By Investing.com - Investing.com South Africa
Trinity Biotech stock rises on successful CGM calibration-free trial - Investing.com India
Trinity Biotech reports positive results for calibration-free CGM By Investing.com - Investing.com South Africa
Trinity Biotech reports positive results for calibration-free CGM - Investing.com India
Trinity Biotech (TRIB) to Release Earnings on Wednesday - Defense World
Trinity Biotech launches preeclampsia testing service for maternal health By Investing.com - Investing.com South Africa
Trinity Biotech launches preeclampsia testing service for maternal health - Investing.com India
Trinity Biotech Plc Sponsored ADR Class A to Host Earnings Call - ACCESS Newswire
Cadence Bank (CADE) Stock: A Year of Market Fluctuations - investchronicle.com
Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround - MarketScreener
Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic and Financial Performance Transformation - MarketScreener
Trinity Biotech receives WHO approval for offshore HIV test manufacturing - Investing.com
Trinity Biotech Appoints New Interim CFO - Investing.com India
Trinity Biotech stock hits 52-week low at $0.62 amid challenges - Investing.com
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process - MarketScreener
Trinity Biotech (NASDAQ:TRIB) Research Coverage Started at StockNews.com - Armenian Reporter
Trinity Biotech stock hits 52-week low at $0.72 amid challenges - Investing.com
Trinity Biotech secures $4m for CGM technology growth - Investing.com
Trinity Biotech secures amended credit to fuel growth - Investing.com
Investor Network: Trinity Biotech Plc Sponsored ADR to Host Earnings Call - ACCESS Newswire
Trinity Biotech stock hits 52-week low at $0.74 amid market challenges - Investing.com
Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial - MarketScreener
Trinity Biotech secures US funding for HIV tests - Investing.com
Trinity Biotech faces US aid policy impact, PPP loan scrutiny - Investing.com
Trinity Biotech announces breakthrough in CGM technology - Investing.com
Trinity Biotech Expands Market Reach with New ADS Offering - Nasdaq
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan - MarketScreener
Trinity Biotech plc Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV - MarketScreener
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements - MarketScreener
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture - MarketScreener
Trinity Biotech : Announces Positive Pre Pivotal Trial Results for Its Next Generation Continuous Glucose Monitor Technology Form 6 K - MarketScreener
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market - MarketScreener
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer - MarketScreener
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology - MarketScreener
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director - MarketScreener
Trinity Biotech plc Announces Chief Financial Officer Changes - MarketScreener
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association - MarketScreener
Trinity Biotech Announces the Appointment of Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development - MarketScreener
Trinity Biotech to Implement ADS Ratio Change By Investing.com - Investing.com India
Trinity Biotech Announces CE Mark of its Covid-19 IgG Elisa Antibody Test - MarketScreener
Trinity Biotech Plc Adr Stock (TRIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):